Patents by Inventor Niyant SHAH

Niyant SHAH has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Combination therapy
    Patent number: 11197857
    Abstract: The present invention provides a combination of a Type I protein arginine methyltransferase (Type I PRMT) inhibitor and a Type II protein arginine methyltransferase (Type II PRMT) inhibitor. The present invention also provides methods for treating cancer in a human in need thereof, the methods comprising administering to the human a combination of a Type I PRMT inhibitor and a Type II PRMT inhibitor, together with at least one of: a pharmaceutically acceptable carrier and a pharmaceutically acceptable diluent, thereby treating the cancer in the human. The present invention further provide a pharmaceutical composition comprising a therapeutically effective amount of a Type I PRMT inhibitor and a second pharmaceutical composition comprising a therapeutically effective amount of a Type II PRMT inhibitor.
    Type: Grant
    Filed: November 30, 2017
    Date of Patent: December 14, 2021
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Olena I. Barbash, Andy Fedoriw, Sarah Gerhart, Ryan G. Kruger, Jenny Laraio, Helai Mohammad, Shane W. Obrien, Jacob Rubin, Niyant Shah, Ping Zhang
  • COMBINATION THERAPY
    Publication number: 20210106580
    Abstract: The present invention provides a combination of a Type I protein arginine methyltransferase (Type I PRMT) inhibitor and a Type II protein arginine methyltransferase (Type II PRMT) inhibitor. The present invention also provides methods for treating cancer in a human in need thereof, the methods comprising administering to the human a combination of a Type I PRMT inhibitor and a Type II PRMT inhibitor, together with at least one of: a pharmaceutically acceptable carrier and a pharmaceutically acceptable diluent, thereby treating the cancer in the human. The present invention further provide a pharmaceutical composition comprising a therapeutically effective amount of a Type I PRMT inhibitor and a second pharmaceutical composition comprising a therapeutically effective amount of a Type II PRMT inhibitor.
    Type: Application
    Filed: November 30, 2017
    Publication date: April 15, 2021
    Inventors: Olena I. BARBASH, Andy FEDORIW, Sarah GERHART, Ryan G. KRUGER, Jenny LARAIO, Helai MOHAMMAD, Shane W. OBRIEN, Jacob RUBIN, Niyant SHAH, Ping ZHANG